PBYI
Puma Biotechnology Inc

6,895
Loading...
Loading...
News
all
press releases
Puma Biotech (PBYI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Puma Biotech (PBYI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks·11d ago
News Placeholder
More News
News Placeholder
Should Value Investors Buy Puma Biotechnology (PBYI) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks·15d ago
News Placeholder
Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?
Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·30d ago
News Placeholder
Should Value Investors Buy Puma Biotechnology (PBYI) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks·1mo ago
News Placeholder
Puma Biotechnology, Inc. (PBYI) Soars to 52-Week High, Time to Cash Out?
Puma Biotech (PBYI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·1mo ago
News Placeholder
PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues
Puma Biotechnology tops second-quarter earnings and revenue estimates as rising Nerlynx sales drive growth.
Zacks·1mo ago
News Placeholder
Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates
Puma Biotech (PBYI) delivered earnings and revenue surprises of +36.36% and +4.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Adma Biologics (ADMA) Q2 Earnings and Revenues Beat Estimates
Adma Biologics (ADMA) delivered earnings and revenue surprises of +7.14% and +0.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Add These 4 Top-Ranked Liquid Stocks to Boost Portfolio Returns
INTU, NTGR, PBYI and DASH make the cut as top liquid stocks, with each boasting strong liquidity, growth attributes and operational efficiency.
Zacks·2mo ago
News Placeholder
Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks·2mo ago

Latest PBYI News

View

Advertisement. Remove ads.

Advertisement. Remove ads.